Umeclidinium for the treatment of uncontrolled asthma

References

• Masoli M, Fabian D, Holt S, et al., The Global Initiative for Asthma. Global burden of asthma. Available at http://www.ginasthma.org/local/uploads/files/GINABurdenReport_1.pdf ( accessed 30 August 2016).
   Google Scholar
• Hashimoto A, Maeda H, Yokoyama M. Augmentation of parasympathetic nerve function in patients with extrinsic bronchial asthma—evaluation by coefficiency of variance of R-R interval with modified long-term ECG monitoring system. Kobe J Med Sci. 1996;42:347–359.
   PubMedGoogle Scholar
• Ayala LE, Ahmed T. Is there loss of protective muscarinic receptor mechanism in asthma? Chest. 1989;96:1285–1291.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Modulation of neurotransmission in airways. Physiol Rev. 1992;72:699–729.
   PubMed Web of Science ®Google Scholar
• Park HW, Yang MS, Park CS, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009;64:778–783.
   PubMed Web of Science ®Google Scholar
• Goyal M, Jaseja H, Verma N. Increased parasympathetic tone as the underlying cause of asthma: a hypothesis. Med Hypotheses. 2010;74:661–664.
   PubMed Web of Science ®Google Scholar
• Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care. 2007;52:833–851.
   PubMed Web of Science ®Google Scholar
• Bos IST, Gosens R, Zuidhof AB, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J. 2007;30:653–661.
   PubMed Web of Science ®Google Scholar
• Ullah MI, Newman GB, Saunders KB. Influence of age on response to ipratropium and salbutamol in asthma. Thorax. 1981;36:523–529.
   PubMed Web of Science ®Google Scholar
• Connolly MJ. Ageing, late-onset asthma and the beta-adrenoceptor. Pharmacol Ther. 1993;60:389–404.
   PubMed Web of Science ®Google Scholar
• Partridge MR, Saunders KB. Site of action of ipratropium bromide and clinical and physiological determinants of response in patients with asthma. Thorax. 1981;36:530–533.
   PubMed Web of Science ®Google Scholar
• Novelli F, Malagrinò L, Dente FL, et al. Efficacy of anticholinergic drugs in asthma. Expert Rev Respir Med. 2012;6:309–319.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Rodrigo C. The role of anticholinergics in acute asthma treatment: an evidence-based evaluation. Chest. 2002;121:1977–1987.
   PubMed Web of Science ®Google Scholar
• Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2013;21(8):CD000060. doi: 10.1002/14651858.CD000060.pub2.
   Google Scholar
• Kerstjens HAM, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–1207.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Bleecker E, Meltzer E, et al. Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: lung function and safety. Eur Respir J. 2013;42(Suppl57):980s (abs 4629).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol Sci. 2010;31:335–343.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Baena-Cagnani CE, Blaiss MS, et al. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) survey: global adult findings. Allergy. 2007;62:668–674.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–844.
   PubMed Web of Science ®Google Scholar
• Adams RJ, Fuhlbrigge A, Guilbert T, et al. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol. 2002;110:58–64.
   PubMed Web of Science ®Google Scholar
• Partridge MR, Van Der Molen T, Myrseth SE, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13.
   PubMedGoogle Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2015. [updated 2015 April; cited 2015 Dec 6]. Available from: www.ginasthma.org/local/uploads/files/GINA_Report_2015.pdf
   Google Scholar
• Bagnasco D, Ferrando M, Varricchi G, et al. A critical evaluation of anti-IL-13 and Anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170(2):122–131. DOI:10.1159/000447692
   PubMed Web of Science ®Google Scholar
• Varricchi G, Senna G, Loffredo S, et al. Reslizumab and eosinophilic asthma: one step closer to precision medicine? Front Immunol. 2017 Mar 10;8:242. doi: 10.3389/fimmu.2017.00242. eCollection 2017.
   Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015 Aug 15;761:168–173. Epub 2015 May 14. DOI:10.1016/j.ejphar.2015.05.020
   PubMed Web of Science ®Google Scholar
• Morrison JF, Pearson SB. The parasympathetic nervous system and the diurnal variation of lung mechanics in asthma. Respir Med. 1991;85:285–289.
   PubMed Web of Science ®Google Scholar
• Cox ID, Hughes DTD, McDonnell KA. Ipratropium bromide in patients with nocturnal asthma. Postgrad Med J. 1984;60:526–528.
   PubMed Web of Science ®Google Scholar
• Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol. 2006;31:181–196.
   PubMed Web of Science ®Google Scholar
• Lee LA, Briggs A, Edwards LD, et al. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma. Respir Med. 2015 Jan;109(1):63–73.
   PubMed Web of Science ®Google Scholar
• O’Connor GT, Sparrow D, Weiss ST. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary-function decline: the Normative Aging Study. Am J Respir Crit Care Med. 1995;152:87e92.
   Web of Science ®Google Scholar
• Lee LA, Yang S, Kerwin E, et al. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med. 2015 Jan;109(1):54–62.
   PubMed Web of Science ®Google Scholar
• Phase A III Parallel Group Study, comparing the efficacy, safety and tolerability of the fixed dose combination (FDC) of fluticasone furoate+Uueclidinium bromide+vilanterol (FF/UMEC/VI) with the FDC of FF/VI in subjects with inadequately controlled asthma. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02924688
   Google Scholar
• Yang S, Lee L, Mallett S, et al. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers. Adv Ther. 2015 Feb;32(2):157–171.
   PubMed Web of Science ®Google Scholar
• Mehta R, Hardes K, Brealey N, et al. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. Int J Chron Obstruct Pulmon Dis. 2015;10:15–23.
   PubMed Web of Science ®Google Scholar
• Yang S, Lee L, Pascoe S. Population pharmacokinetics modeling of inhaled umeclidinium for adult patients with asthma. Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):79-88. doi: 10.1007/s13318-016-0331-8.
   PubMed Web of Science ®Google Scholar
• Rothman ML, Beltran P, Cappelleri JC, et al. Mayo/FDA Patient-reported outcomes consensus meeting group. Patient-reported outcomes: conceptual issues. Value Health. 2007;10(Suppl. 2):S66–S75.
   Google Scholar